HPV16/18 E5, a promising candidate for cervical cancer vaccines, affects SCPs, cell proliferation and cell cycle, and forms a potential network with E6 and E7

Liao,Shujie; Deng,Dongrui; Hu,Xiaoji; Wang,Wei; Li,Li; Li,Wei; Zhou,Jianfeng; Xu,Gang; Meng,Li; Wang,Shixuan; Ma,Ding

doi:10.3892/ijmm.2012.1168

HPV16/18 E5, a promising candidate for cervical cancer vaccines, affects SCPs, cell proliferation and cell cycle, and forms a potential network with E6 and E7

Authors:
- Shujie Liao
- Dongrui Deng
- Xiaoji Hu
- Wei Wang
- Li Li
- Wei Li
- Jianfeng Zhou
- Gang Xu
- Li Meng
- Shixuan Wang
- Ding Ma
View Affiliations

Affiliations: Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: October 30, 2012 https://doi.org/10.3892/ijmm.2012.1168
Pages: 120-128

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The spindle checkpoint proteins (SCPs), which sense the existence of misaligned sister chromatids during mitosis and meiosis, are essential for cell proliferation and differentiation. Therefore, the role of SCPs in carcinogenesis is gaining increased attention. In this study, we analysed the expression of Bub1 and Mad2 in clinical samples by immunohistochemistry (IHC) during the development of cervical cancer (CC), and we explored the interaction of Bub1/Mad2 with different proteins through immunoprecipitation (IP). Furthermore, we analysed the characteristics of four different cell models of human papillomavirus (HPV)16/18 E5. We demonstrated that with the progression of CC, the expression of Bub1 and Mad2 was gradually reduced under the influence of HPVE5. Overexpression of HPV16/18 E5 significantly increased cell proliferation, as well as the percentage of cells in the S phase. In addition, the levels of p21, Bub1 and Mad2 were markedly decreased in E5-expressing cells. Therefore, HPV16/18 E5 plays a critical role in carcinogenesis and is a potential therapeutic target in CC treatment.

View Figures

View References

1	Tang Z, Sun Y, Harley SE, Zou H and Yu H: Human Bub1 protects centromeric sister-chromatid cohesion through Shugoshin during mitosis. Proc Natl Acad Sci USA. 101:18012–18017. 2004. View Article : Google Scholar : PubMed/NCBI
2	Yu H: Regulation of APC-Cdc20 by the spindle checkpoint. Curr Opin Cell Biol. 14:706–714. 2002. View Article : Google Scholar : PubMed/NCBI
3	Nasmyth K: Segregating sister genomes: the molecular biology of chromosome separation. Science. 297:559–565. 2002. View Article : Google Scholar : PubMed/NCBI
4	Cleveland DW, Mao Y and Sullivan KF: Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell. 112:407–421. 2003. View Article : Google Scholar : PubMed/NCBI
5	Tang Z, Shu H, Oncel D, et al: Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle checkpoint. Mol Cell. 16:387–397. 2004. View Article : Google Scholar : PubMed/NCBI
6	Genther Williams SM, Disbrow GL, Schlegel R, et al: Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res. 65:6534–6542. 2005.PubMed/NCBI
7	Burgert HG, Ruzsics Z, Obermeier S, et al: A subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol. 269:273–318. 2002.PubMed/NCBI
8	Vazquez-Ortiz G, Ciudad CJ, Pina P, et al: Gene identification by cDNA arrays in HPV-positive cervical cancer. Arch Med Res. 36:448–458. 2005. View Article : Google Scholar : PubMed/NCBI
9	Medema RH, Klompmaker R, Smits VA and Rijksen G: P21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA replication or stress-activated kinases. Oncogene. 16:431–441. 1998. View Article : Google Scholar : PubMed/NCBI
10	Freitas S, Moore DH, Michael H and Kelley MR: Studies of apurinic/apyrimidinic endonuclease/ref21 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. Clin Cancer Res. 9:4689–4694. 2003.PubMed/NCBI
11	Kozak M: At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol. 196:947–950. 1987. View Article : Google Scholar : PubMed/NCBI
12	Biswas C, Kell B, Mant C, et al: Detection of human papillomavirus type 16 early-gene transcription by reverse transcription-PCR is associated with abnormal cervical cytology. J Clin Microbiol. 35:1560–1564. 1997.PubMed/NCBI
13	Winer J, Jung CK, Shackel I and Williams PM: Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 270:41–49. 1999. View Article : Google Scholar
14	Krawczyk E, Suprynowicz FA, Sudarshan SR and Schlegel R: Membrane orientation of the human papillomavirus type 16 E5 oncoprotein. J Virol. 84:1696–1703. 2010. View Article : Google Scholar : PubMed/NCBI
15	Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol. 182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
16	Gao P and Zheng J: High-risk HPV E5-induced cell fusion: a critical initiating event in the early stage of HPV-associated cervical cancer. J Virol. 7:238–240. 2010. View Article : Google Scholar : PubMed/NCBI
17	Boulenouar S, Weyn C, Van Noppen M, et al: Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion, migration and invasion of trophoblastic cells. Carcinogenesis. 31:473–480. 2010. View Article : Google Scholar : PubMed/NCBI
18	Pedroza-Saavedra A, Lam EW, Esquivel-Guadarrama F and Gutierrez-Xicotencatl L: The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the down-regulation of p27(Kip1). Virology. 400:44–52. 2010. View Article : Google Scholar : PubMed/NCBI
19	Kivi N, Greco D, Auvinen P and Auvinen E: Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene. 27:2532–2541. 2008. View Article : Google Scholar : PubMed/NCBI
20	Nath R, Mant CA, Kell B, et al: Analyses of variant human papillomavirus type-16 E5 proteins for their ability to induce mitogenesis of murine fibroblasts. Cancer Cell Int. 6:192006. View Article : Google Scholar : PubMed/NCBI
21	Kim MK, Kim HS, Kim SH, et al: Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochem Pharmacol. 80:1930–1935. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ruesch MN and Laimins LA: Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J Virol. 71:5570–5578. 1997.PubMed/NCBI
23	Tsao YP, Li LY, Tsai TC and Chen SL: Human papillomavirus type 11 and 16 E5 represses p21 (WafI/SdiI/CipI) gene expression in fibroblasts and keratinocytes. J Virol. 70:7535–7539. 1996.PubMed/NCBI
24	Defeo-Jones D, Vuocolo GA, Haskell KM, et al: Papillomavirus E7 protein binding to the retinoblastoma protein is not required for viral induction of warts. J Virol. 67:716–725. 1993.PubMed/NCBI
25	Maufort JP, Shai A, Pitot HC and Lambert PF: A role for HPV16 E5 in cervical carcinogenesis. Cancer Res. 70:2924–2931. 2010. View Article : Google Scholar : PubMed/NCBI